Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

Share this content:

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

Sponsor and Collaborators     
Memorial Sloan-Kettering Cancer Center
Merck
Phoenix Children's Hospital
Penn State Children's Hospital
Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center
Children's Hospital Colorado
University of Florida
Alberta Children's Hospital
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Children's Mercy Hospital & Clinics
All Children's Hospital

Contacts
Tanya Trippett,, MD     212-639-8267     
Christine Pratilas, MD     212-639-3964     
             
Investigator    
Tanya Trippett, MD     
Memorial Sloan-Kettering Cancer Center     

ClinicalTrials.gov Identifier
NCT01294670

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs